Abstract: Prostate cancer is a widespread problem among men, with >160 000 new cases in 2017 alone. Androgen deprivation therapy is commonly used in prostate cancer treatment to block androgens required for cancer growth, but disease relapse after androgen deprivation therapy is both common and severe. Changes in androgen receptor signaling from androgen deprivation therapy have been linked to therapeutic resistance and tumor progression. Resistant cells can become reprogrammed to undergo epithelial-mesenchymal transition, a phenotypic switch from benign, epithelial cells to a mobile cell with mesenchymal traits. In these cells, attachment to their epithelial cell layer is no longer required for survival. Anoikis is a form of cell death that occurs when detachment from other cells and the basement membrane occurs. Epithelial cells have been shown to undergo epithelial-mesenchymal transition, avoid anoikis induction and progress to a metastatic phenotype. In prostate cancer progression to advanced disease, epithelial-mesenchymal transition induction (characterized by loss of epithelial cellular attachment protein E-cadherin) correlates with a higher Gleason score, tumor progression, increased metastasis and higher biochemical recurrence. The concept of interfacing epithelial-mesenchymal transition with anoikis in the tumor microenvironment landscape will be discussed here, with focus on the significance of the functional exchange between the two processes in therapeutic targeting of advanced disease. The current evidence on the impact of loss of cell-cell contact, acquisition of chemoresistance, immune escape and metastatic spread in advanced tumors in response to transforming growth factor-b on prostate cancer metastasis will be also discussed. The signaling cross-talk between transforming growth factor-b and androgen receptor signaling will be interrogated as a new therapeutic platform for the development of combination strategies to impair prostate cancer metastasis.
Introduction
Clinical problem of prostate cancer non-specific process resulting in cell lysis and inflammation. 5, 6 Cancer cells have developed mechanisms to avoid programmed pathways anoikis and apoptosis, engaging in abnormal survival mechanisms to sustain their aberrant growth. 5 Evasion of apoptosis and emergence of anoikis resistance are critical mechanisms contributing to cancer initiation, metastasis and therapeutic resistance, thus rendering restoration of cell death mechanisms an attractive therapeutic platform for the treatment of advanced recurrent tumors. [7] [8] [9] [10] Overcoming apoptosis is essential for initial tumor formation, acquisition of metastatic properties and secondary site colonization. 7, 11, 12 Mechanistically, there are two primary pathways to initiate apoptosis: (i) the extrinsic/death-receptor (CD95 or FAS) pathway; and (ii) the intrinsic/mitochondrial pathway. 13 Extrinsic apoptosis is activated by death-receptor ligand binding, such as Fas ligand or TRAIL. 5 Binding of these ligands induces receptor polymerization and subsequent activation of caspase-8. 8, 14 Caspase-8 triggers the activation of executioner caspases, such as caspase-3, 6 and 7, which carry out the apoptosis signaling cascade. 15 Intrinsic apoptosis begins through intracellular signals, such as mitochondrial or endoplasmic reticulum stress and DNA damage leading to apoptosome formation (cytochrome c, Apaf1 and caspase-9), and subsequent activation of executioner caspases 3, 6 and 7. 5 Extracellular signals can trigger the intrinsic pathway; for example, a lack of survival signals (e.g. growth factor withdrawal) can result in intrinsic pathway activation. 16, 17 In response to pro-apoptotic proteins, such as Bak and Bax, are activated while anti-apoptotic proteins, Bcl-2 and Bcl-xL, are subdued. 18, 19 An increase in pro-apoptotic proteins, bak/bax, and decrease in anti-apoptotic proteins, Bcl-2/Bcl-xL, causes cytochrome c release, apoptosome formation, caspase cascade activation and apoptosis. 15, 20 Anoikis is apoptosis that is induced on cell detachment from the ECM. 7, 11 Pathologically normal epithelial and endothelial cells adhere to ECM, and die through anoikis, if ECM contact is lost. Mechanisms conferring resistance to anoikis facilitate the cancer cell dissemination functionally contributing to metastasis and therapeutic resistance. 14, 21 Under conditions of normal homeostasis, detachment of epithelial or endothelial cells from the ECM leads to an increase of FAS and Fas ligand, FAS polymerization and caspase-8 activation, and ultimately anoikis induction.
14 ECM detachment directly causes increased Bak activity and decreased Bcl-xL activity, thus triggering apoptosis through the intrinsic pathway. 19 Cells resistant to anoikis fail to activate caspase-8 after losing ECM anchoring, and engage BclxL activity and consequently survive. 14, 22 Normal cell-ECM interactions are mediated through integrins, transmembrane proteins that are critical for cell attachment, survival, differentiation, migration and invasion. 15 Signal transduction from the extracellular environment to the intracellular network through the integrin network dictates anoikis resistance, cell invasion and metastasis outcomes. 17 Through aberrant integrin function, epithelial or endothelial cells can avoid anoikis by signal modifications including the integrins directly, downstream signaling effectors 20, 21 or activation of survival pathways dependent on integrins. 5, 16, 23, 24 AR signaling can induce anoikis through downregulation of p38, and ultimately suppress metastasis. 25 Intracellular reactive oxygen species in prostate cancer have been shown to activate prosurvival signals and anoikis resistance, with sensitivity to anoikis restored on anti-oxidant treatment in prostate epithelial cells. 26 Chronic, persistent redox damage leads to Src activation regardless of cellular attachment, conferring anoikis resistance to highly damaged cells. 26 If detachment of cells from the prostate epithelium occurs, basal progenitor cells are stimulated to divide and differentiate into an epithelial phenotype to replace them. 27 EMT in cancer cell dynamics EMT is a process through which an epithelial cell acquires migratory and invasive characteristics, and is a pivotal mechanism utilized by cells to escape their native microenvironment. 18 Cells at the leading edge of tumors have undergone EMT, implicating the process in tumor development and expansion. 28 Epithelial cells are normally very cohesive, held together in a single layer through cell-cell interactions navigated by cadherins, specifically E-cadherin. 29 Adhering junctions are formed to connect stable epithelial cells, containing E-cadherin and other proteins, such as b-catenin and actin, to form a stable junction. 29 Through linking the cellular actin network to that of the neighboring cell, adhering junctions effectively form a single, unified sheet from individual epithelial cells. 29 Loss of E-cadherin expression and adhering junctions directly causes a loss in normal epithelial cell polarity and de-differentiation into an amorphous cell without its anchor to other epithelial cells (Fig. 1) . On induction of EMT, adherens junctions disintegrate, releasing b-catenin from the junction into the cell cytosol, where it can translocate to the nucleus and act as a transcription factor; 29 furthermore, other transcriptional regulators, such as E-cadherin repressors, Snail and Twist. 29 Epithelial cells have a distinct polarity, with proteins localized to either the apical or basolateral membrane surface. Membrane proteins, claudin and occludin, maintain these junctions, and are associated with cytosolic proteins, such as Ankyrin, to maintain polarity. 30 In order for epithelial cells to lose their polarity, these tight junctions must be dissolved. The phenotypic landscape of EMT can be characterized by the loss of epithelial markers (e.g. E-cadherin, b-catenin, occludin) and a gain of mesenchymal markers (e.g. N-Cadherin, Zeb-1/2, vimentin, Snail, Twist) in addition to a loss of cell polarity. 18 Signaling pathways through extracellular receptors can trigger EMT reprogramming, such as platelet-derived growth factor receptor, FGFR, TGF-b and IGF-1R. 31 Intracellular signaling pathways, such as PI3K, Akt and mTOR, can also navigate EMT outcomes. 31 A key event in EMT induction is transcriptional regulation by primary transcription factors Snail, Slug and Twist, which suppress expression of epithelial markers (E-cadherin) and upregulate corresponding mesenchymal proteins (N-cadherin). 31 On acquisition of the mesenchymal phenotype, cells no longer require attachment for survival; therefore, cells that have undergone EMT do not die through anoikis, but acquire freedom and survival, liberated from the "home" epithelial layer. 30 The key transcriptional regulators of EMT, such as Slug and Snail, confer anoikis resistance by targeting cell-cell adhesion molecules, as well as intracellular signaling effectors. 7 Recent evidence supports the ability of Ecadherin to sensitize cells to anoikis, an intuitive role if the structural integrity of adhering junctions is disturbed. 30 Transcriptional repressors such as these eventually cause silencing of the gene through epigenetic control. 32 Posttranslationally, E-cadherin can be degraded/cleaved or endocytosed under control of GTPase Arf6. 32 Consequential to EMT induction, E-cadherin transcriptional activation and expression are decreased. Loss of E-cadherin has been shown to make cells resistant to anoikis, as shown in E-cadherin knockout models, indicating that loss of an epithelial phenotype is directly linked to loss of anoikis-mediated cell killing. 30 ,33 E-cadherin loss leads to a decrease in other proteins, such as b-catenin and Ankyrin-G. When not sequestered in adhering junctions with E-cadherin, b-catenin is released from the cytosol into the nucleus, thus acting as a transcription factor in control of genes regulating proliferation and migration. While knockout of E-cadherin decreases anoikis, simultaneous loss of both E-cadherin and b-catenin restores sensitivity to anoikis, showing that b-catenin is also a common control denominator between EMT and anoikis. 30, 34 Ankyrin-G, a protein that connects the cytoskeleton to the cell membrane, is also lost when cells undergo EMT and downregulate E-cadherin. 30 Loss of ankyrin-G leads to reduced expression of p14ARF, a tumor suppressor that promotes anoikis -therefore, anoikis is also regulated through interactions between E-cadherin and ankyrin-G, further implicating traditional EMT players as regulators of anoikis. 30 The impact of interfacing EMT and anoikis in the tumor microenvironment landscape includes loss of cell-cell contact, acquisition of chemoresistance, immune escape 35 and metastatic spread. 18 In advanced disease, loss of E-cadherin expression correlates with a higher Gleason score, 19 extended local tumor progression, higher clinical stage, increased likelihood of metastasis and a higher chance of biochemical recurrence after radical prostatectomy. 36 Thus, an integrated EMT signature of the tumor landscape provides a unique biomarker value in prostate cancer progression.
Threading the metastatic journey
Initiation of metastasis begins with the transformation of phenotype from benign to malignant, cell proliferation, and formation of an initial solid tumor. Neovascularization then occurs before the tumor can exceed 2 mm. 6 Anoikis suppression by cancer cells promotes tumor neovascularization, making anoikis resistance not only mandatory for cell dissociation from its microenvironment, but also necessary for tumor expansion. 6 After volume expansion and the accumulation of mutations in the cancer cells, some cells manage to disassociate from the associated basement membrane/ECM and connective tissue, degrade, travel through ECM, and gain access to lymphatic or blood vessels. 29 Cancer cells must evade anoikis in order to continue surviving in circulation. Anoikis evasion has been correlated with an increasing number of prostate CTC, 37 with the number of CTC correlated with poor prognosis, late disease recurrence and patient mortality, showing the importance of anoikis evasion in disease progression. 38, 39 The joint effect of undergoing EMT and avoiding anoikis is an increase in both cellular invasiveness and metastasis. 40, 41 Anoikis resistance confers invasive properties in cancer cells, leading to metastasis, contributing to therapeutic resistance and ultimately impacting cancer patient mortality. 42 For more than two decades, work from our group and others has established the significance of anoikis evasion and activation of survival pathways as leading contributors to the emergence of CRPC. 9, 21, 43 The Src-navigated survival pathway, whose activation is functionally linked to the emergence of CRPC therapeutic resistance, leads to anoikis resistance through engaging the PI3K/Akt (phosphoinositide-3 kinase and protein kinase B, respectively) pathways. 9 Furthermore, there is the loss of the PTEN tumor suppressor gene encoding for a protein that directly suppresses the PI3K/Akt pathway; loss of PTEN therefore increases PI3K/Akt activity, increases cell survival and is common in poorly differentiated CRPC. 10 In addition, overexpression of Bcl-2 and Bcl-xL results in apoptosis resistance, and is related to tumor survival after chemotherapy and radiotherapy. 44 A transcriptional repressor of E-cadherin, Snail, activates cell survival pathways such as PI3/Akt, inhibits executor caspase-3 and antagonizes p-53 mediated apoptosis, in addition to downregulating E-cadherin. 45 Snail has been directly associated with chemoresistance. 45 Snail is activated by Notch1, a protein associated with EMT, and commonly found in advanced tumors and recurring prostate cancer. 46 Twist, another transcriptional repressor, is associated with poor prognosis and the emergence of the mesenchymal phenotype, 47 and can mechanistically upregulate Bcl-2, towards promoting enhanced survival and resistance to radiotherapy and chemotherapy. 48, 49 Extravasation has likely already occurred at the time of a patient's diagnosis, thus rendering preventative measures to impair tumor metastatic spread a challenge. 50 Cells are either invading or dividing, but not both simultaneously; 51 thus invasive cells are arrested in G 1 , capable of re-entering the cell cycle on settling in a secondary location. 51 Cells that have evaded anoikis and are circulating are not sensitive to classic chemotherapeutics, which target dividing cells , allowing the arrested cells to persist and seed secondary tumors. 51, 52 Phenotypic reversal of EMT to MET is required in the colonizing tumor cells to retain their growth kinetics at the distant site of metastasis and return to a dividing phenotype. 53 Specific targeted therapies with kinase inhibitors cause cancer cells to release a therapy-induced secretome that kills therapy-resistant clones and promotes survival of sensitive cells. 54 EMT in the tumor microenvironment
TGF-b
TGF-b signals from the stroma and tumor microenvironment have a great effect on cancer cells. 29, 47, 55 TGF-b signaling in cancer is a complicated process, and can be simplified by understanding TGF-b as having a dual function. In normal cells and initial stages of cancer, TGF-b signaling is a tumor suppressor, but in later stages of cancer switches to a more classical growth factor, and is associated with increased metastatic potential and worse patient prognosis. 55 A mechanism for this switch in TGF-b responses is not yet fully understood. Excess TGF-b is correlated with rapid disease metastasis, and cancer metastases often contain more TGF-b than the original seed/solid tumor. 55 Metastatic cells from primary prostate tumors that have formed "quiescent micrometastatic deposits" in the secondary location of bone are stimulated to maintain their invasive characteristics through endogenous TGF-b signaling. 29 These deposits of a single or a few cells can further develop into large metastases through continued EMT promotion. 29 Efforts to understand/define the contribution of TGF-b to EMT in the tumor microenvironment led to a link between high metastases occurrence and EMT of metastatic cells in the pre-metastatic niche (as illustrated in Fig. 1) . 29, 47 Mechanistically, TGF-b signaling begins with the TGF-b ligand binding a TbRII, which activates TbRI, further initiating signal transduction through intracellular Smad2 and Smad3 phosphorylation. 56 Active/phosphorylated Smad2 and 3 translocate to the nucleus and form a complex with Smad4. 56 The complex of Smad2, 3 and 4 acts as a transcription factor, recruits other cofactors, and works at increasing the production of EMT transcription factors Snail, Twist and Zeb1/2. 56 Through this canonical Smad signaling, TGF-b is linked to EMT. In a non-canonical/Smad independent manner, TGF-b can determine EMT outcomes through downstream effectors MAP kinase, and PI3K/Akt pathways. 57 In addition to promoting EMT, TGF-b also regulates the production of matrix metalloproteinases, thereby enhancing the ability for cells undergoing EMT to migrate through the extracellular matrix as it is being digested by matrix metalloproteinases. 47 TGF-b signaling also dictates the actin cytoskeleton remodeling by regulating cofilin expression and increasing filopodia formation, and giving cells the ability to migrate and metastasize. 46 
AR axis
Activation of AR signaling in prostate epithelial cells occurs on ligand binding and translocates to the nucleus where it functions as a transcription factor. However, in many cancers, there is aberrant AR protein and signaling, with >20 splicing mutations known. 58 AR can gain many functions, including constitutive activity, the ability to bind androgenic metabolites and resistance to anti-androgen therapy, through mutations in the ligand-binding domain. 58 Interestingly enough, microtubule-targeting taxane chemotherapy can also block AR translocation to the nucleus and therefore inhibit AR transcriptional activity regardless of the AR mutation load. 58, 59 Dihydrotestosterone, the circulating form of androgen, causes suppression of E-cadherin expression through an increase in Snail. 31 However, this effect requires a threshold low level of AR, suggesting an inverse relationship between the level of AR expression and the degree of EMT induction through dihydrotestosterone/AR signaling. 31 It is important to note that the most common therapy for prostate cancer is ADT, which causes a downregulation of the AR in response to low circulating androgen levels. 31, 60 Therefore, in an inadvertent way, a common therapy could be promoting an aggressive phenotype through induction of EMT. Work from this laboratory has shown that use of an AR antagonist, such as abiraterone, can negate the EMT changes induced by canonical androgen signaling and ADT. 31 By preventing EMT, AR antagonists function on more than one level as a treatment therapy; stopping androgen-dependent growth while also promoting an epithelial phenotype. 31 Androgen signaling linked to EMT contributes to the high number of cases of metastatic CRPC, and there is a growing body of evidence supporting the involvement of EMT in the development of CRPC. 31, 60, 61 Low AR expression induced by ADT contributes to the aggressive nature of CRPC through inducing EMT, facilitating metastasis and decreasing therapeutic efficacy. 31, 60 This evidence has established that low AR signaling advances prostate cancer, but it is also known that the gain of function AR mutations and AR overexpression promote prostate cancer growth as well. 31, 62 One current way of avoiding therapy resistance and AR downregulation found in standard ADT is by using intermittent ADT, where androgen therapy is administered with scheduled gaps, avoiding AR downregulation with the promise of improved clinical response to ADT. 31 Unfortunately, many patients with CRPC become resistant to second-generation anti-androgens, enzalutamide and abiraterone. Resistance can develop through various mechanisms, including AR mutations, splice variants, constitutive activation, increased AR expression or increased androgen synthesis from adrenal or intratumoral sources. 62 Because many AR splice variants and mutants have an altered C-terminal ligand-binding domain, the un-mutated N-terminal domain has become a target of AR inhibition in recent research in order to treat the variants and mutants as effectively as the wild-type AR. 58 
Targeted therapeutics in prostate cancer
Current therapeutic options for mCRPC are limited in efficacy and have high rates of therapeutic resistance. Options include androgen axis-targeting agents, abiraterone and enzalutamide; the microtubule stabilizing taxane chemotherapeutic, cabazitaxel (the second-generation taxane designed to overcome resistance to first-generation taxane docetaxel); radiotherapy with radium-223; and limited immunotherapy with sipuleucel-T. 62, 63 A summary of the current therapeutics targeting cellular fate processes in prostate tumors is shown in Table 1 .
Anoikis-inducing agents
Quinazoline-based a1-adrenoreceptor antagonists, such as doxazosin and terazosin, have been previously shown to induce anoikis in urological cancers. 64 Doxazosin has been heavily studied in prostate cancer, and induces apoptosis by activating caspase-3, which cleaves FAK. 65 Active FAK suppresses anoikis, but cleaved FAK is non-functional and the cell undergoes anoikis. 65 Studies from our group on the structural optimization of doxazosin led to the generation of a lead derivative, DZ-50, which exerts a potent antitumor effect through anoikis induction in both prostate and renal cancers. 64, 66 Induction of anoikis by DZ-50 was shown by the loss of integrin-linked kinase and talin expression on prostate cancer lines PC3 and DU145, 33 leading to prostate tumor growth suppression and impairing metastasis in tumor models. 33, 64 In renal cell carcinoma, DZ-50 and doxazosin results in significant suppression of migration and invasion, whereas quinazoline derivatives exert anti-angiogenic properties through anoikis, impairing tumor vascularity and growth. 64 Activation of p38 by platycodin D activates p38 MAPK signaling and increases anoikis in other cancers. 67 Another therapeutic approach for anoikis-resistant mRCC centers on the fact that tyrosine receptor kinase B is commonly overexpressed in mRCC. 68 Treatment of mRCC tumors using firstline drug, sorafenib, leads to the emergence of resistance in cells overexpressing tyrosine receptor kinase B; inhibiting tyrosine receptor kinase B sensitized cells to anoikis and sorafenib, with a therapeutic promise for anoikis-resistant tumors. 69 
EMT/MET interconversions in the microenvironment
First-line treatment for patients with CRPC is to administer taxane chemotherapy, a microtubule targeting chemotherapeutic drug that functions by stabilizing microtubules and inducing apoptotic cell death, 70 as well as impairing AR activity and interfering with EMT. 59 The second-generation taxane, cabazitaxel, is clinically used only after patients have failed to respond to first-generation taxanes treatment and hormonal therapy/second-generation anti-androgens. Recent work from our laboratory identified the ability of cabazitaxel to reverse EMT to MET in both androgen-responsive and CRPC prostate cancer cells, showing that the taxane mechanism of action extends beyond mitotic arrest and apoptosis. 70 Interconversion of EMT to MET and subsequently inducing tumor redifferentiation through cabazitaxel treatment could be utilized to overcome therapeutic resistance to both AR-targeted and microtubule-targeting taxane therapies. 70 Combination of ADT with taxane chemotherapy into a fashioned chemohormonal therapy provides a therapeutic advantage to patients with advanced disease, compared with ADT alone, and calls for sequencing of the treatment regimes to increase survival. 71 Recent optimization strategies include combination approaches of docetaxel with a Notch inhibitor to induce MET-88. Inhibiting Notch causes deactivation of Snail, the transcriptional repressor of E-cadherin, thereby restoring transcription of E-cadherin, assisting the cancer cells in maintaining an endothelial phenotype, metastatic cell reattachment and promoting MET. 53 Taxane chemotherapy can prevent cell division through inhibiting microtubule dynamics, and a Notch inhibitor for restoration of E-cadherin expression has the potential to convert cancerous cells back to the epithelium through MET. Selective targeting of the stromal cells in the tumor microenvironment emerges as an attractive option for eradicating prostate cancer. 72 Endothelial cells surrounding prostate tumors have been found to secrete growth factors such as interleukin-6. 73 Phenotypic changes in the landscape of the prostate microenvironment after castration engage signaling through interleukin-6, AR downregulation and associated upregulation of TGF-b, to promote tumor cell survival and invasiveness. 74 Blocking interleukin-6 signaling in cocultured cancer epithelial cells and endothelial cells abrogated the effect of endothelial cells, enabling a new therapeutic platform. 74 Exploitation of EMT/MET interconversion within the tumor microenvironment enables development of new therapeutic platforms for targeted therapies against advanced tumors.
47 Local TGF-b signaling can induce morphology changes in the tumor through EMT regulators, Snail and Twist. 47 TGF-b inhibitors are presented with clinical benefit in patients involved in ongoing clinical trials. 75 In the prostate microenvironment, androgens secreted in an autocrine/ paracrine manner rather than endocrine, enable androgendependent tumor growth after ADT. 75 To combat this, the second-generation anti-androgen, abiraterone, is given because it inhibits androgens from both auto/paracrine and endocrine sources, including the adrenals. 75 
Integrin-targeting agents
Integrins are not only involved in cell-cell adhesion, but also navigate several signal transduction networks from the tumor microenvironment to intracellular signals, thus becoming attractive targets for cancer therapeutics. 17 Specifically, the avb3 and avb5 integrins have a pharmacological inhibitor, cilengitide, designed to antagonize integrin signaling and disrupt cell motility through the microenvironment. 17 However, in a mCRPC phase II clinical trial reported in 2011, cilengitide treatment did not meet standards for patient improvement. 76 In this trial, the majority of patients had disease progression during drug treatment, hypothesized to be from cancer cells increasing integrin production and signaling in response to the drug treatment. 76 Alternative integrin signaling blocking therapies include monoclonal antibodies, CNTO 95 and MEDI-522, in development for blocking integrin signaling in prostate cancer. 77 Despite disappointing clinical trials of cilengitide, the avb3 integrin has been found necessary for prostate cancer metastasis to the bone, supporting integrin signaling as an attractive drug target if more effective therapies can be designed. 75 
Anti-angiogenic agents
Increased expression of VEGFA and PDGFb in tumors regulates local blood flow to dividing cells and target organs. 31 Sunitinib and sorafenib are two small-molecule tyrosine kinase inhibitors with potent anti-angiogenic properties through inhibiting VEGF receptor 2 and PDGF receptor-b, depriving the tumor of signals that contribute to its survival. 78 Bevacizumab is a monoclonal antibody that binds and neutralizes VEGF, 79 and has been in clinical use through phase II and III clinical trials for the treatment of advanced renal cell carcinoma. 36 Axitinib and pazopanib are newer anti-angiogenic drugs that work by inhibiting VEGFRs, causing decreased vascular growth, increased vascular permeability and tumor cell apoptosis. 47, 55 Still in clinical trials, antiangiogenic drugs, aflibercept and cediranib, are being tested in combination therapy with prednisone and/or docetaxel for treatment of mCRPC. 75 The anoikis-inducing agent, DZ-50, was first shown by this laboratory to impair angiogenesis through inducing downregulation of angiogenesis modulator, thrombospondin 1, further increasing the translational interest in this novel attractive therapeutic. 32, 69 PI3K/Akt/mTOR inhibitors mTOR is an evolutionarily conserved serine/threonine kinase downstream of the PI3K/Akt survival pathway that has been implicated in human cancers, including prostate cancer (Fig. 2) . Phosphorylation and aberrant activation of this pathway results in cell growth and proliferation without specific growth or survival signals, giving selective advantage to those cells and facilitating tumorigenesis. 80 Though mTOR is intricately intertwined in many growth signaling pathways, phosphorylation of mTOR is present in prostate tumors, increasing cancer cell survival through cell cycle promotion. The imidazo-quinoline derivative, NVP-BEZ235, is a dual PI3K/mTOR inhibitor that shows antitumor activity against prostate tumors through limiting vasculature leakage in the tumor tissue microenvironment and reducing tumor interstitial fluid pressure effects. [81] [82] [83] NVP-BEZ235 is effective against prostate tumors regardless of PTEN status. 82 Combination treatment with Akt inhibitor, MK-2206, and mTOR inhibitor, MK-8669 (ridaforolimus), inhibits CRPC in a preclinical model. [83] [84] [85] The Akt inhibitor, MK-2206, is currently undergoing clinical trials in non-urological cancers as a combination therapy with initial promising results. 86 
Conclusions and future directions
The therapeutic challenge in patients with advanced metastatic CRPC is to effectively increase survival to more than a few months. At the molecular level, the sequencing of therapeutic targeting to reverse EMT to MET and induce anoikis in metastatic cancer cells might be an emerging paradigm to be exploited. Although EMT and resistance to anoikis are currently a therapeutic challenge, it is a characteristic that separates cancer cells from normally functioning cells, and any process that is unique to cancer cells can be exploited in therapeutic use. Therapeutics that target EMT are in their infancy, and require further development before a reliable, widely used therapeutic platform is constructed. EMT programming can bypass the cell's ability to die on detachment, causing a temporal interconversion of its phenotype, and extending survival, entering the bloodstream, metastasizing, invading secondary tissues and successfully colonizing in the distant site. The clinical benefits of exploiting the anoikis-EMT connection is prevention of metastasis before it can begin while overcoming therapy resistance. Recent advances in molecular profiling of the prostate tumor landscape have defined several molecular signatures based on dissection of significant processes operational in prostate cancer cells. How can a therapeutic window in these temporal events then be capturing a subset of tumor epithelial cells ready to be targeted after the anoikis resistance offense is downregulated by the EMT effectors? Prostate cancer is one of the most lethal male cancers in the USA today, but restoration of anoikis sensitivity and a reprogramming of EMT towards cell execution will aid in overcoming therapeutic resistance and increasing survival (Fig. 2) .
Avoidance of anoikis is essential for a successful metastatic event. Inhibiting anoikis and related cellular events, including EMT, increased motility and chemoresistance, would restore a sort of neutrality to the tumor through prevention of disease spread. To block extravasation would mean blocking metastatic events before they can begin, and keep disease states in a realm where therapies are more effective -treating the primary tumor rather than advanced disease. When metastatic events occur, almost all therapeutic regimes universally fail. The "holy grail" of effectively treating metastatic disease might be to prevent the metastic journey and cell colonization from occurring in the first place by overcoming resistance to anoikis through sensitizing the cells to EMT/MET reversal and acquisition of the epithelial phenotype.
